FluoGuide A/S

Denmark · owned by Independent (Denmark) · fluoguide.com · 20 vendors

FluoGuide A/S is a clinical-stage biotechnology company focused on developing drugs that make cancer fluorescent to maximize surgical outcomes. Their technology aims to improve precision surgery for cancer patients by enabling surgeons to better visualize and remove cancerous tissue. The company is headquartered in Denmark.

Resilience scores

Disruption prediction

FluoGuide A/S has an estimated 11% probability of disruption in the next 6 months.

7 of FluoGuide A/S's 20 vendors monitored for disruptions.

Technology vendors

Services catalogue

1 service in catalogue across 1 category; runs on 20 sub-vendors.

Insights

Last updated 2026-08-15 · revision 13

20 direct vendors, 196 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 5/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

FluoGuide A/S demonstrates medium migration readiness, facing several challenges. The internal tech stack, centered on WordPress, is traditional and not designed for cloud-native, containerized, or microservices architectures. A migration would likely involve a "lift-and-shift" of the existing WordPress environment or a significant re-platforming effort to leverage modern cloud benefits, rather than a straightforward cloud-native deployment. The company faces complex regulatory and data residency requirements, notably GDPR and EU MDR. GDPR mandates specific data residency for EU personal data, requiring processing within the EU/EEA or countries with adequacy decisions, and the use of Standard Contractual Clauses for third-country transfers. EU MDR may impose additional data localization requirements for clinical trial and medical device development data. These requirements will significantly complicate cloud provider selection, data architecture, and security controls during any migration. Financially, as a pre-revenue company, funding for a substantial migration project would be reliant on investor capital, potentially limiting the scope, speed, or ambition of migration efforts. While the exact number of vendors is unclear (due to the "Total Vendors: 0" data point), reliance on specific platforms like WordPress (which requires hosting) and SaaS services such as Google Analytics, YouTube, and Vimeo could introduce vendor lock-in risks depending on contract terms, data portability features, and the complexity of integration. On the positive side, the current tech stack primarily supports a public web presence, suggesting that the overall scope of a migration might be less complex than for an organization with extensive custom enterprise applications, potentially making a "lift-and-shift" of the WordPress site more manageable. Additionally, the presence of vendor HQs in 5 unique countries suggests some experience in managing geographically diverse vendor relationships, which could be beneficial when selecting new cloud or service providers during a migration.

Compliance

8 in-scope frameworks identified; showing 3.

EU Clinical Trials Regulation — Assessment Required

This is the primary sector-specific regulation for FluoGuide's core business. The EU CTR (Regulation 536/2014), fully applicable since January 2023 via the CTIS (Clinical Trials Information System), governs all clinical trials of medicinal products in the EU. FluoGuide has completed Phase I and Phase II trials of FG001 in brain cancer and head & neck cancer. Non-compliance with CTR requirements (trial authorization, informed consent, safety reporting, data integrity) can result in trial suspension, marketing authorization refusal, and significant reputational damage. The risk is High because clinical trial compliance is existential for a clinical-stage biotech — regulatory failure could halt the entire pipeline.

Evidence: https://fluoguide.com/pipeline/pipeline/, https://fluoguide.com/pipeline/fg001/, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines, https://euclinicaltrials.eu/, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0536

Nasdaq First North Growth Market — Assessment Required

FluoGuide is listed (or transitioning to) Nasdaq First North Growth Market in Sweden, which subjects it to EU Market Abuse Regulation (MAR, Regulation 596/2014) and Nasdaq First North disclosure rules. For a clinical-stage biotech, clinical trial results, regulatory decisions, and partnership announcements are highly material information requiring timely disclosure. Failure to disclose inside information promptly, or improper handling of insider lists, can result in significant regulatory sanctions from Finansinspektionen (Sweden) or the Danish FSA. The risk is High given the materiality of clinical trial outcomes for share price.

Evidence: https://fluoguide.com/investor/filings-archive/, https://fluoguide.com/investor/compliance/, https://fluoguide.com/mfn_news/, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0596, https://www.nasdaq.com/solutions/nasdaq-first-north

EU Medical Device Regulation — Assessment Required

FluoGuide's technology involves fluorescence-guided surgery systems, including collaboration with Intuitive Surgical (robotic surgery systems) and laser system manufacturers. The imaging/camera systems used in conjunction with FG001 for intraoperative fluorescence guidance may be classified as medical devices under EU MDR 2017/745. If FluoGuide's technology platform includes any hardware or software components (e.g., imaging algorithms, AI-assisted tumor detection), these could trigger MDR obligations. The risk is Medium because the primary regulatory pathway appears to be pharmaceutical (EMA/CTR), but combination product or device-drug combination classification could add MDR requirements.

Evidence: https://fluoguide.com/technology/fluorescent-guidance-to-surgical-oncologists/, https://fluoguide.com/about/fluoguide/, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745, https://www.dkma.dk/en/medical-devices

Financials

Three-year financials

Financial Resilience Score: 3/10

FluoGuide A/S is a pre-commercial clinical-stage biotech with no revenue and persistent operating losses driven by R&D spending on its FG001 program. The company relies entirely on equity funding to reach commercialisation or a partnering deal, with multiple capital raises since its 2020 IPO on Spotlight Stock Market. Operating losses have widened from approximately DKK -15 to -20 million in FY2021 to DKK -30 to -40 million in FY2023 as Phase II trials ramped up across two indications. While the company has demonstrated clinical validation with positive Phase II readouts in glioblastoma and head-and-neck cancer, giving it partnering/out-licensing optionality, its financial resilience is inherently weak due to single-asset concentration on FG001, absence of revenue, and continuous cash burn. The 2025-2026 strategic repositioning, including the planned move from Spotlight to Nasdaq First North and updated 2026 outlook, suggests a phase of financial and strategic uncertainty with significant dilution risk for shareholders. The capital-light model relative to systemic oncology developers and access to Nordic biotech grants (e.g., Danish skattekredit) provide some support, but overall resilience remains low.

Key strengths: Positive Phase II clinical readouts in glioblastoma and head-and-neck cancer, Access to public equity markets via Spotlight (moving to Nasdaq First North), Capital-light business model relative to systemic oncology drug developers, Support from Nordic biotech ecosystem (grants, tax credits, academic partnerships), Partnering/out-licensing optionality from clinical validation

Risk factors: No revenue and persistent operating losses (DKK -30 to -40M annually), Complete reliance on equity funding with significant dilution risk, Single-asset concentration on FG001 / uPAR targeting, Small scale with high key-person risk (10-20 employees), Competitive landscape with approved alternatives (Lumisight, Cytalux, Gleolan/5-ALA), Strategic repositioning and exchange move signals financial uncertainty

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report